Why the study?
Does TCV-116 (angiotensin AT1 receptor antagonist) reduce cardiac hypertrophy and altered gene expression in TGR(mRen2)27 transgenic rats compared to other antihypertensive combinations?
Does TCV-116 (angiotensin AT1 receptor antagonist) reduce cardiac hypertrophy and altered gene expression in TGR(mRen2)27 transgenic rats compared to other antihypertensive combinations?
In a transgenic rat model, angiotensin AT1 receptor antagonism regressed cardiac hypertrophy and remodeling more effectively than other antihypertensive agents with similar blood pressure-lowering effects, highlighting the role of the local renin-angiotensin system.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for AT1-specific hypertrophy regression beyond BP control; leaves open translation to human therapy.
Ohta et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: